Calgary, January 9, 2025 - Nimble Science, a precision medicine company empowering biopharma and digestive health companies with access to previously unreachable multi-omic intestinal data, announces the launch of its revolutionary data platform to advance health innovation. This cutting-edge platform is designed to transform therapeutic and diagnostic development across various healthcare fields, including gastrointestinal, neurological, metabolic, consumer, and animal health.
In tandem with the launch, Nimble Science proudly welcomes Prof. Eran Segal, a globally recognized computational biologist from the Weizmann Institute of Science with deep expertise in personalized medicine, nutrition, and the complex interplay between genetics, the microbiome, and health, to its Scientific Advisory Board (SAB). Prof. Segal will provide strategic guidance as the company pioneers innovative solutions leveraging its growing database of precision intestinal data.
The new SIMBA GI Health Data Platform is powered by Nimble Science's proprietary SIMBA Capsule, a first-in-class ingestible device that collects and preserves precise, high-quality samples directly from the small intestine. The SIMBA Capsule has been integrated into over 19 global clinical studies, delivering solutions to customers evaluating disease conditions and therapeutic product interaction. The launch of our data platform as a service now empowers users with data quality indexing and access to valuable insights derived from a growing repository of matched metagenomic data sets from healthy and disordered fecal and small intestinal samples. This includes data from individuals suffering from SIBO, IBS, and IBD.
"The ability to provide high quality, scalable data insights is a turning point in healthcare innovation for Nimble and our partners, and opens the door to discoveries previously out of reach," said Sabina Bruehlmann, Co-Founder and CEO of Nimble Science. "The addition of Professor Eran Segal to the SAB, speaks to the quality of the SIMBA Capsule data and its massive potential for health innovation. "
Prof. Eran Segal, who leads a multidisciplinary team at the Weizmann Institute of Science, shared his enthusiasm for joining Nimble’s SAB: "The small intestinal microbiome is a critical frontier in understanding and improving human health. Nimble's innovative platform offers an unprecedented opportunity to map microorganisms in this vital region at scale, shedding light on disease mechanisms and enabling the development of transformative diagnostics and therapeutics and targeted interventions for a vast range of health conditions."
Building upon the successful launch, Nimble Science is actively expanding partnerships across the healthcare, life sciences, and consumer product sectors to unlock the full potential of this groundbreaking multi-omic data and the expansion of the data platform into clinical solutions.
About Nimble Science
Nimble Science is a precision medicine company providing a multi-omic data platform to advance healthcare innovation. Its SIMBATM Capsule, a clinically validated ingestible device, enables unparalleled access to the microenvironment of the small intestine. Nimble's mission is to revolutionize health innovation by empowering researchers and clinicians with transformative tools to unlock new possibilities in diagnostics, therapeutics, and beyond.
The company is supported by leading life science investors, including Fusion Fund, Seventure Partners, Joyance Partners and Ki Tua Fund, who recognize the transformative potential of Nimble's groundbreaking approach to health product innovation and precision medicine.
For further information please contact:
Comments